Register Financial Advisors LLC Acquires 3,038 Shares of Organon & Co. (NYSE:OGN)

Register Financial Advisors LLC raised its holdings in Organon & Co. (NYSE:OGN) by 7.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,046 shares of the company’s stock after purchasing an additional 3,038 shares during the period. Register Financial Advisors LLC’s holdings in Organon & Co. were worth $866,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Prevail Innovative Wealth Advisors LLC purchased a new position in Organon & Co. in the 4th quarter valued at approximately $3,336,000. Cantor Fitzgerald Investment Advisors L.P. bought a new position in shares of Organon & Co. in the fourth quarter worth $1,850,000. New York State Teachers Retirement System grew its position in shares of Organon & Co. by 20.1% in the fourth quarter. New York State Teachers Retirement System now owns 348,226 shares of the company’s stock valued at $5,021,000 after purchasing an additional 58,321 shares in the last quarter. State of Alaska Department of Revenue raised its stake in shares of Organon & Co. by 417.8% during the 4th quarter. State of Alaska Department of Revenue now owns 157,249 shares of the company’s stock valued at $2,267,000 after purchasing an additional 126,882 shares during the period. Finally, Allianz Asset Management GmbH lifted its holdings in Organon & Co. by 156.5% during the 4th quarter. Allianz Asset Management GmbH now owns 1,900,554 shares of the company’s stock worth $27,406,000 after purchasing an additional 1,159,519 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of OGN stock traded up $0.11 on Friday, reaching $20.70. The company’s stock had a trading volume of 2,030,214 shares, compared to its average volume of 2,399,278. The company has a market capitalization of $5.32 billion, a P/E ratio of 5.06, a PEG ratio of 0.90 and a beta of 0.87. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $24.08. The stock’s 50 day simple moving average is $20.41 and its 200-day simple moving average is $17.97. The company has a quick ratio of 1.15, a current ratio of 1.65 and a debt-to-equity ratio of 181.35.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.31. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The business had revenue of $1.62 billion for the quarter, compared to analyst estimates of $1.57 billion. As a group, equities analysts predict that Organon & Co. will post 4.3 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 13th. Investors of record on Monday, May 13th were paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 5.41%. The ex-dividend date of this dividend was Friday, May 10th. Organon & Co.’s dividend payout ratio is currently 27.38%.

Wall Street Analyst Weigh In

Several research analysts have commented on OGN shares. The Goldman Sachs Group raised their target price on Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Piper Sandler raised their price objective on shares of Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, April 29th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.